December, 1996 (3)

• Switching amino-terminal cytoplasmic domains of alpha(1,2)fucosyltransferase and alpha(1,3)galactosyltransferase alters the expression of H substance and Galalpha(1,3)Gal.
  Osman N, McKenzie IF, Mouhtouris E, Sandrin MS
  J Biol Chem. 1996 Dec; 271(51):33105-33109
• The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors.
  Kershaw MH, Darcy PK, Trapani JA, Smyth MJ
  J Leukoc Biol. 1996 Dec; 60(6):721-728
• Defence against the immune barrage: helminth survival strategies.
  Riffkin M, Seow HF, Jackson D, Brown L, Wood P
  Immunol Cell Biol. 1996 Dec; 74(6):564-574

November, 1996 (7)

• Nuclear transport of granzyme B (fragmentin-2). Dependence of perforin in vivo and cytosolic factors in vitro.
  Jans DA, Jans P, Briggs LJ, Sutton V, Trapani JA
  J Biol Chem. 1996 Nov; 271(48):30781-30789
• Xenospecific cytotoxic T lymphocytes use perforin- and Fas-mediated lytic pathways.
  Smyth MJ, Sutton VR, Kershaw MH, Trapani JA
  Transplantation. 1996 Nov; 62(10):1529-1532
• Malaria vaccine.
  Ruff T
  Lancet. 1996 Nov; 348(9038):1378-1379
• Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies.
  Smyth MJ, O'Connor MD, Trapani JA, Kershaw MH, Brinkworth RI
  J Leukoc Biol. 1996 Nov; 60(5):555-562
• A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes.
  Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA, Trapani JA, Bird PI
  J Biol Chem. 1996 Nov; 271(44):27802-27809
• Recognition of an octapeptide sequence by multiple Gal alpha(1,3)Gal-binding proteins.
  Vaughan HA, Oldenburg KR, Gallop MA, Atkin JD, McKenzie IFC, Sandrin MS
  Xenotransplantation. 1996 Nov; 3(11):18-23
• An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
  Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ
  J Virol. 1996 Nov; 70(11):8010-8018

October, 1996 (5)

• The Ced-3/interleukin 1beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32.
  Srinivasula SM, Fernandes-Alnemri T, Zangrilli J, Robertson N, Armstrong RC, Wang L, Trapani JA, Tomaselli KJ, Litwack G, Alnemri ES
  J Biol Chem. 1996 Oct; 271(43):27099-27106
• Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity.
  Greenway A, Azad A, Mills J, McPhee D
  J Virol. 1996 Oct; 70(10):6701-6708
• Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
  Tachedjian G, Mellors J, Bazmi H, Birch C, Mills J
  J Virol. 1996 Oct; 70(10):7171-7181
• Breast cancer immunotherapy: current status and future prospects.
  Apostolopoulos V, McKenzie IF, Pietersz GA
  Immunol Cell Biol. 1996 Oct; 74(5):457-464
• Myopathy and spontaneous Pasteurella pneumotropica-induced abscess formation in an HIV-1 transgenic mouse model.
  Dickie P, Mounts P, Purcell D, Miller G, Fredrickson T, Chang LJ, Martin MA
  J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Oct; 13(2):101-116

September, 1996 (7)

• Vulnerability in emergency situations.
  Toole MJ
  Lancet. 1996 Sep; 348(9031):840
• The incidence of hepatitis B infection in Australia: an epidemiological review.
  Kaldor JM, Plant AJ, Thompson SC, Longbottom H, Rowbottom J
  Med J Aust. 1996 Sep; 165(6):322-326
• Polyvalent vaccines and the national immunisation schedule.
  Thompson SC
  Med J Aust. 1996 Sep; 165(6):346-347
• Managing HIV. Part 8: Controlling an epidemic. 8.6 Epidemiological surveillance for HIV and AIDS.
  Kaldor JM, Crofts N
  Med J Aust. 1996 Sep; 165(5):268-271
• Elimination of sequence ambiguities by a single-step modification of a solid-phase, single-stranded sequencing protocol.
  Lawson VA, McPhee DA, Deacon NJ
  Biotechniques. 1996 Sep; 21(3):356-358
• Human immunodeficiency virus grown in CD4-expressing cells is associated with CD4.
  Hartley CA, Gilbert MJ, Brigido L, Elbeik T, Levy JA, Crowe SM, Mills J
  J Gen Virol. 1996 Sep; 77 ( Pt 9):2015-2023
• HIN-200: a novel family of IFN-inducible nuclear proteins expressed in leukocytes.
  Dawson MJ, Trapani JA
  J Leukoc Biol. 1996 Sep; 60(3):310-316

August, 1996 (7)

• Redirected cytotoxic effector function. Requirements for expression of chimeric single chain high affinity immunoglobulin e receptors.
  Kershaw MH, Darcy PK, Hulett MD, Hogarth PM, Trapani JA, Smyth MJ
  J Biol Chem. 1996 Aug; 271(35):21214-21220
• Managing HIV. Part 8: Controlling an epidemic. 8.3 Prospects for a preventive HIV vaccine.
  Kent SJ, Clancy RL, Ada GL
  Med J Aust. 1996 Aug; 165(4):212-215
• The changing prevalence of hepatitis C virus types in injecting drug users between 1971 and 1994.
  Moaven LD, Crofts N, McCaw R, Bowden DS
  Med J Aust. 1996 Aug; 165(4):233
• Feline calicivirus strain differentiation using monoclonal antibody analysis in an enzyme-linked immuno-flow-assay.
  McArdle F, Dawson S, Carter MJ, Milton ID, Turner PC, Meanger J, Bennett M, Gaskell RM
  Vet Microbiol. 1996 Aug; 51(3-4):197-206
• Quantifying phagocytosis of Mycobacterium avium complex by human monocytes in whole blood.
  Hewish MJ, Meikle AM, Hunter SD, Crowe SM
  Immunol Cell Biol. 1996 Aug; 74(4):306-312
• The first hit: circumstances surrounding initiation into injecting.
  Crofts N, Louie R, Rosenthal D, Jolley D
  Addiction. 1996 Aug; 91(8):1187-1196
• Why should Australia adopt universal infant hepatitis B vaccination?
  Thompson SC, Oman K
  Aust N Z J Public Health. 1996 Aug; 20(4):436-439

July, 1996 (18)

• In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains.
  Fernandes-Alnemri T, Armstrong RC, Krebs J, Srinivasula SM, Wang L, Bullrich F, Fritz LC, Trapani JA, Tomaselli KJ, Litwack G, Alnemri ES
  Proc Natl Acad Sci U S A. 1996 Jul; 93(15):7464-7469
• Extracellular mutations of non-obese diabetic mouse FcgammaRI modify surface expression and ligand binding.
  Gavin AL, Hamilton JA, Hogarth PM
  J Biol Chem. 1996 Jul; 271(29):17091-17099
• Screening--sensitivity, specificity and hepatitis C.
  Stevenson EM, Thompson SC, Crofts N
  Med J Aust. 1996 Jul; 165(2):120
• Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages.
  Lewin SR, Sonza S, Irving LB, McDonald CF, Mills J, Crowe SM
  AIDS Res Hum Retroviruses. 1996 Jul; 12(10):877-883
• The heroin trial we had to have.
  Crofts N
  Med J Aust. 1996 Jul; 164(11):694-695
• Injecting and sexual risk-taking among young injecting drug users.
  Crofts N, Louie R, Rosenthal D
  Venereology. 1996 Jul; 91(2):114-118
• Risk behaviours for blood-borne viruses in a Victorian prison.
  Crofts N, Thompson S, Wale E, Hernberger F
  Aust N Z J Criminol. 1996 Jul; 29(1):20-28
• Cloning and expression of the recombinant mouse natural killer cell granzyme Met-ase-1.
  Kelly JM, O'Connor MD, Hulett MD, Thia KY, Smyth MJ
  Immunogenetics. 1996 Jul; 44(5):340-350
• Transmission of hepatitis C virus: rates, routes, and cofactors.
  MacDonald M, Crofts N, Kaldor J
  Epidemiol Rev. 1996 Jul; 18(2):137-148
• Yes to transplants.
  McKenzie, IFC
  Nature. 1996 Jul; 380(6574):478
• Managing HIV. Part 6: People living with HIV. 6.7 Travellers with HIV.
  Ruff TA
  Med J Aust. 1996 Jul; 165(1):43-45
• Reduction of the major porcine xenoantigen Ga1 alpha(1,3)Gal by expression of alpha(1,2)fucosyltransferase.
  Sandrin MS, Fodor WL, Cohney S, Mouhtouris E, Osman N, Rollins SA, Squinto SP, McKenzie IFC
  Xenotransplantation. 1996 Jul; 3(1):131-140
• Negotiated safety? Sexual practices among young gay injecting drug users.
  Sharp R, Crofts N, Sattler G, Marcus L, Meade J, Wallace J, Wood R
  Venereology. 1996 Jul; 9(2):106-112
• HIV testing of patients diagnosed with genital Chlamydia trachomatis in Victoria.
  Thompson S, McEachern A, Stevenson E
  Venereology. 1996 Jul; 9(3):172-175
• Tumour immunotherapy against MUC1 expressing tumours using mannan MUC1.
  Apostolopoulos V, Pietersz GA, Acres B, Osinski C, Thynne G, Xing PX, Karanikas V, Vaughan HA, Hwang L, Popovski V, Lees C, Ong CS, McKenzie IFC
  in Breast Cancer - Advances in Biology and Therapeutics. 1996 Jul
• Processing of the Nedd2 precursor by ICE-like proteases and granzyme B.
  Harvey NL, Trapani JA, Fernandes-Alnemri T, Litwack G, Alnemri ES, Kumar S
  Genes Cells. 1996 Jul; 1(7):673-685
• A new approach to fecal occult blood testing based on the detection of haptoglobin.
  Xing PX, Young GP, Ho D, Sinatra MA, Hoj PB, McKenzie IF
  Cancer. 1996 Jul; 78(1):48-56
• Interactions between the ectodomains of haemagglutinin and CD46 as a primary step in measles virus entry.
  Devaux P, Loveland B, Christiansen D, Milland J, Gerlier D
  J Gen Virol. 1996 Jul; 77 ( Pt 7):1477-1481

June, 1996 (8)

• New onset of Graves' disease following subclinical hypothyroidism in a woman with systemic lupus erythematosus (SLE)
  Mallon DF, Hollingsworth PN
  Aust N Z J Med. 1996 Jun; 26(3):424-425
• Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes.
  Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S
  J Virol. 1996 Jun; 70(6):3863-3869
• Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.
  Apostolopoulos V, Pietersz GA, McKenzie IF
  Vaccine. 1996 Jun; 14(9):930-938
• Is HIV screening being requested appropriately? The experience of a Victorian public health laboratory.
  Darlington R, Thompson SC, Forsyth JR
  Aust N Z J Public Health. 1996 Jun; 20(3):247-253
• Reinventing hepatitis C: from interferon deficiency to control.
  Wodak A, Crofts N
  Aust N Z J Public Health. 1996 Jun; 20(3):231-232
• Hepatitis C transmission through tattooing: a case report.
  Thompson SC, Hernberger F, Wale E, Crofts N
  Aust N Z J Public Health. 1996 Jun; 20(3):317-318
• A novel substrate-binding pocket interaction restricts the specificity of the human NK cell-specific serine protease, Met-ase-1.
  Smyth MJ, O'Connor MD, Trapani JA, Kershaw MH, Brinkworth RI
  J Immunol. 1996 Jun; 156(11):4174-4181
• Impact of a mass vaccination campaign against a meningitis epidemic in a refugee camp.
  Haelterman E, Boelaert M, Suetens C, Blok L, Henkens M, Toole MJ
  Trop Med Int Health. 1996 Jun; 1(3):385-392

May, 1996 (2)

• Translation is enhanced after silent nucleotide substitutions in A+T- rich sequences of the coding region of CD46 cDNA.
  Milland J, Christiansen D, Thorley BR, McKenzie IF, Loveland BE
  Eur J Biochem. 1996 May; 238(1):221-230
• Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3.
  Sayers TJ, Lloyd AR, McVicar DW, O'Connor MD, Kelly JM, Carter CR, Wiltrout TA, Wiltrout RH, Smyth MJ
  J Leukoc Biol. 1996 May; 59(5):763-768

April, 1996 (6)

• Annulate lamellae and lytic HAV infection in vitro.
  Marshall JA, Borg J, Coulepis AG, Anderson DA
  Tissue Cell. 1996 Apr; 28(2):205-214
• Strategies to overcome the anti-Gal alpha (1-3)Gal reaction in xenotransplantation.
  McKenzie IF, Osman N, Cohney S, Vaughan HA, Patton K, Mouhtouris E, Atkin JD, Elliott E, Fodor WL, Squinto SP, Burton D, Gallop MA, Oldenburg KR, Sandrin MS
  Transplant Proc. 1996 Apr; 28(2):537
• The interaction of macrophage and non-macrophage tropic isolates of HIV-1 with thymic and tonsillar dendritic cells in vitro.
  Cameron PU, Lowe MG, Sotzik F, Coughlan AF, Crowe SM, Shortman K
  J Exp Med. 1996 Apr; 183(4):1851-1856
• Unprotected sexual intercourse in 'safe' contexts: Deciding what matters most.
  Parnell B
  Venereology. 1996 Apr; 9(2):104-105
• HIV in the mentally ill.
  Checkley GE, Thompson SC, Crofts N, Mijch AM, Judd FK
  Aust N Z J Psychiatry. 1996 Apr; 30(2):184-194
• A profile of HIV testing in Victoria to the end of 1993. Victorian Collaborative Group on HIV and AIDS Surveillance (VCGHAS).
  Thompson SC, Stevenson EM, Crofts N
  Aust N Z J Public Health. 1996 Apr; 20(2):165-171

March, 1996 (6)

• Response: Attenuated HIV Vaccine: Caveats.
  Deacon NJ, McPhee DA, Crowe S, Learmont J, Mills J
  Science. 1996 Mar; 271(5257):1791-1792
• Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV.
  Crowe S, Cooper DA, Chambers DE
  Med J Aust. 1996 Mar; 164(5):290-295
• Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9.
  Sandrin MS, Henning MM, Lo MF, Baker E, Sutherland GR, McKenzie IF
  Immunogenetics. 1996 Mar; 43(1-2):13-19
• Engineering of recombinant soluble CD46: an inhibitor of complement activation.
  Christiansen D, Milland J, Thorley BR, McKenzie IF, Mottram PL, Purcell LJ, Loveland BE
  Immunology. 1996 Mar; 87(3):348-354
• A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro.
  Christiansen D, Milland J, Thorley BR, McKenzie IF, Loveland BE
  Eur J Immunol. 1996 Mar; 26(3):578-585
• Determining the Nutritional Status of the Elderly in post-cold war Russia.
  Toole MJ, Serdula M
  Am J Public Health. 1996 Mar; 86(3):299-301

February, 1996 (5)

• Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis.
  Trapani JA, Browne KA, Smyth MJ, Jans DA
  J Biol Chem. 1996 Feb; 271(8):4127-4133
• Managing HIV. Part 3: Mechanisms of disease. 3.3 How HIV leads to opportunistic infections.
  Crowe SM, Kornbluth RS
  Med J Aust. 1996 Feb; 164(3):171-173
• Managing HIV. Part 3: Mechanisms of disease. 3.1 Structure and function of HIV.
  Cunningham AL, Dwyer DE, Mills J, Montagnier L
  Med J Aust. 1996 Feb; 164(3):161-165
• Dendritic cells and the replication of HIV-1.
  Cameron P, Pope M, Granelli-Piperno A, Steinman RM
  J Leukoc Biol. 1996 Feb; 59(2):158-171
• Once more unto the breach: controlling hepatitis C in injecting drug users.
  Wodak A, Crofts N
  Addiction. 1996 Feb; 91(2):181-184

January, 1996 (3)

• Membrane junctions associated with rubella virus infected cells.
  Lee JY, Bowden DS, Marshall JA
  J Submicrosc Cytol Pathol. 1996 Jan; 28(1):101-108
• Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue.
  McGavin CH, Land SA, Sebire KL, Hooker DJ, Gurusinghe AD, Birch CJ
  AIDS. 1996 Jan; 10(1):47-53
• Molecular cloning of the gene coding for pig alpha1-->2fucosyltransferase.
  Cohney S, Mouhtouris E, McKenzie IF, Sandrin MS
  Immunogenetics. 1996 Jan; 44(1):76-79